Please ensure Javascript is enabled for purposes of website accessibility

Browse by products

Featured content

  • abinScience provides high-quality tools for studying viruses, superbugs, and parasites, including monkeypox, Ebola, and other emerging pathogens, supporting diagnostics, vaccine development, and therapeutic discovery.
  • abinScience provides tools for studying Alzheimer's, Parkinson's, and Huntington's disease, supporting biomarkers, diagnostics, and therapy development in neuroscience.
  • abinScience provides tools for studying therapeutic targets, including CD3E, CTLA4, PD1, PDL1, B7-H3, CEA, CD200R1, SIRPA, and CCR8, supporting biomarkers, diagnostics, and therapy development.
  • abinScience offers anti-dsRNA antibodies (J2, K1, K2), widely recognized in virology, immunology, and RNA research for their exceptional specificity and sensitivity, empowering scientists to explore the RNA world
  • Reliable antibodies for botulinum, ricin, tetanus, and other toxins, enabling sensitive detection and toxin research.
  • High-specificity antibodies and ELISA kits for key targets like TNF-α, IL-6, IFN-γ, PD-1, and CTLA-4, enabling reliable cytokine detection and immune regulation studies.
  • Specific antibodies for MHC I, MHC II, and related molecules, supporting antigen presentation, immune response, and disease research.
  • Targeting tumor-associated carbohydrate antigens (Tn, STn, MUC1, CA15-3, CA72-4) to support cancer immunotherapy and biomarker research
  • Model organisms are vital tools used by researchers around the globe. These organisms share many genes with humans, are easily maintained in the lab, and have short generation times that make it easy to study the effects of genetic manipulations.
  • About abinScience

    News

  • This article systematically reviews the core biological characteristics, current research hotspots, and detection methods for ASFV. It elucidates the virus's complex structure, mechanisms of immunosuppression leading to high pathogenicity, and the emergence of recombinant strains, while also discussing vaccine strategies and key diagnostic targets.
  • Allergy research is advancing toward a new era of precision medicine and immunotherapy, with innovations like CAR-T cell therapies offering solutions for severe allergies. The global allergy market is projected to reach $30 billion by 2030, fueled by growing demand for diagnostic and therapeutic tools. The World Allergy Organization (WAO) underscores the critical need for early diagnosis and prevention, collaborating with iCAALL to enhance global education and awareness. Researchers can partner with abinScience for tailored support, while distributors have a unique opportunity to expand their portfolios. Act now to join this transformative movement in allergy care and research!
  • This article explores Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a high-fatality pathogen first identified in 2012, focusing on its structure, pathogenesis, and vaccine development challenges. It highlights the virus’s spike protein and DPP4 receptor interaction, with recent Nature findings revealing a MERS-CoV-like mink coronavirus using ACE2, underscoring zoonotic risks (Wang et al., 2025). The article details immune responses, including IL-6, TNFα, IFNγ, and CRP-driven cytokine storms, and discusses vaccine hurdles like antibody-dependent enhancement. abinScience’s recombinant proteins and antibodies are presented as essential tools for virology and immunology research, empowering studies on MERS-CoV and related coronaviruses.
  • Discover the Chikungunya virus (CHIKV) structure, key proteins, and pathogenesis, with insights from the 2025 Foshan outbreak and global epidemiology. Learn about WHO’s warnings on CHIKV epidemic risks and explore abinScience’s advanced research tools, including recombinant proteins and antibodies, designed to support vaccine and antiviral development for this mosquito-borne disease.
  • Uncover the science behind mosquito-borne diseases like Chikungunya’s crippling joint pain, Dengue’s complex serotypes, West Nile’s neurological risks, Yellow Fever’s historic threat, Zika’s congenital dangers, and Japanese Encephalitis’s brain inflammation. Learn about the challenges of controlling these viruses and explore cutting-edge lab tools for diagnostics, vaccine development, and research. abinScience offers specialized antibodies and recombinant proteins to target viral proteins, empowering scientists to fight these global health threats effectively.
  • Since April 2025, China has faced a resurgence of COVID-19, with positivity rates in outpatient and inpatient settings rising sharply from 7.5% to 16.2% and 3.3% to 6.3%, respectively. Southern provinces report higher infection rates than the north, with the Omicron NB.1.8.1 variant driving the surge due to its enhanced immune escape capabilities. Symptoms remain mild, including sore throat, low-grade fever, and cough. The pandemic is expected to peak in late May and subside by late June. abinScience offers high-quality SARS-CoV-2-related proteins and antibodies to support cutting-edge virology research.
  • The abinScience InVivoMAb™ Plus series offers over 400 high-quality in vivo antibodies, validated for purity, specificity, and functionality, ideal for research in cancer, autoimmune diseases, and infectious diseases. This page details the activity validation experiments and ELISA tests of anti-PD-1 and anti-PD-L1 antibodies in mouse models (B16-F10 and CT26), demonstrating significant tumor suppression and antigen-binding capabilities. The product list includes a range of antibodies and isotype controls designed for immune regulation and tumor immunotherapy, supported by batch stability and traceability.
  • Discover the biology, structure, and pathogenesis of Hepatitis C Virus (HCV), including its virion structure and immune evasion strategies. Explore the latest advances in HCV vaccine development and effective tools from abinScience, such as recombinant proteins and antibodies, to support antiviral research. Updated July 30, 2025, this resource offers insights into DAA therapy and vertical transmission challenges.
  • Recent research has uncovered a critical role for erythropoietin (EPO) in tumor immune evasion. Tumor cells secrete EPO, which, through the EPOR signaling pathway, suppresses the immune function of macrophages, aiding tumors in escaping immune surveillance. Blocking the EPO/EPOR signaling enhances the efficacy of PD-1 immunotherapy, offering a novel strategy for cancer treatment.
  • This schematic illustration highlights four key research areas in tuberculosis (TB) studies: ESAT-6/CFP-10 as core antigens for immunodiagnostic platforms (IGRA, ELISPOT), HspX as a biomarker for latent infection and stress response, KatG and InhA as primary targets for drug resistance mechanism analysis, and Ag85 series antigens for vaccine target validation. Designed for scientific publications, this figure supports research in TB diagnostics, immune mechanisms, and drug resistance studies.
  • A groundbreaking study from the University of Birmingham, published in eBioMedicine, reveals that immune aging may precede and drive rheumatoid arthritis (RA) rather than being a mere consequence of chronic inflammation. By examining T-cell and B-cell subsets, researchers found early signs of immune senescence—such as reduced naïve CD4 T cells and increased age-associated B cells (ABCs)—in patients with joint pain and undifferentiated arthritis, even before RA diagnosis. The novel IMM-AGE score, which quantifies immune aging, correlates with elevated inflammatory markers (IL-6, TNFα, CRP) and predicts RA progression. These findings suggest that RA follows an “aging first, inflammation later” trajectory, offering new avenues for early detection and intervention by targeting immune aging pathways.
  • The World Health Organization reports over 400,000 cholera cases across 31 countries by mid-August 2025, with nearly 5,000 deaths, highlighting the disease's persistent global threat. Caused by Vibrio cholerae, cholera spreads through contaminated water and food, leading to severe dehydration and death if untreated. This article explores the bacterium’s structure, virulence factors like cholera toxin, pathogenesis, vaccine progress, and public health significance. It also highlights abinScience’s role in providing antibodies and recombinant proteins to support cholera research, emphasizing the need for continued scientific and social efforts to combat this deadly disease.